Polysaccharide structure dictates mechanism of adaptive immune response to glycoconjugate vaccines.
Adaptive Immunity
/ drug effects
Animals
Antibody Formation
/ immunology
Antigens
/ immunology
Epitopes
/ immunology
Female
Flow Cytometry
Glycoconjugates
/ immunology
Meningococcal Vaccines
/ immunology
Mice
Mice, Inbred BALB C
N-Acetylneuraminic Acid
Neisseria meningitidis
/ immunology
Polysaccharides, Bacterial
/ immunology
T-Lymphocytes, Helper-Inducer
/ immunology
Vaccines, Conjugate
/ immunology
Tcarb
antigen presentation
glycoconjugate
group C Neisseria meningitidis
vaccine
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
02 01 2019
02 01 2019
Historique:
pubmed:
5
12
2018
medline:
19
3
2019
entrez:
5
12
2018
Statut:
ppublish
Résumé
Glycoconjugate vaccines are among the most effective interventions for preventing several serious infectious diseases. Covalent linkage of the bacterial capsular polysaccharide to a carrier protein provides CD4
Identifiants
pubmed: 30510007
pii: 1816401115
doi: 10.1073/pnas.1816401115
pmc: PMC6320544
doi:
Substances chimiques
Antigens
0
Epitopes
0
Glycoconjugates
0
Meningococcal Vaccines
0
Polysaccharides, Bacterial
0
Vaccines, Conjugate
0
serogroup C meningococcal conjugate vaccine
0
N-Acetylneuraminic Acid
GZP2782OP0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
193-198Subventions
Organisme : NIAID NIH HHS
ID : R01 AI089915
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI109764
Pays : United States
Commentaires et corrections
Type : CommentIn
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
J Immunol. 1999 Apr 15;162(8):4740-4
pubmed: 10202015
Lancet Infect Dis. 2005 Jan;5(1):21-30
pubmed: 15620558
J Immunol. 2017 Jul 15;199(2):598-603
pubmed: 28566369
Cell. 2004 May 28;117(5):677-87
pubmed: 15163414
JAMA. 2005 Dec 21;294(23):3019-23
pubmed: 16414950
Infect Immun. 1999 Dec;67(12):6375-84
pubmed: 10569753
J Exp Med. 1970 Aug 1;132(2):283-99
pubmed: 4101345
Infect Immun. 1982 Jul;37(1):15-22
pubmed: 6809623
BMJ. 2015 Apr 01;350:h1554
pubmed: 25832102
Nat Protoc. 2012 Dec;7(12):2180-92
pubmed: 23196974
J Exp Med. 1970 Aug 1;132(2):261-82
pubmed: 4101344
Eur J Immunol. 1971 Jan;1(1):10-7
pubmed: 14978856
Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5183-8
pubmed: 18381820
J Immunol Methods. 1999 Jul 30;227(1-2):161-8
pubmed: 10485263
J Immunol. 1995 Aug 1;155(3):1074-8
pubmed: 7636181
J Immunol. 1993 Sep 1;151(5):2419-25
pubmed: 8360471
Vaccine. 2009 May 21;27(24):3137-44
pubmed: 19446183
Nat Rev Drug Discov. 2010 Apr;9(4):308-24
pubmed: 20357803
Nat Rev Immunol. 2004 Apr;4(4):308-12
pubmed: 15057789
Eur J Immunol. 1971 Jan;1(1):18-27
pubmed: 14978857
Infect Immun. 1993 Nov;61(11):4760-6
pubmed: 8406875
Pediatr Infect Dis J. 2012 Oct;31(10):1069-73
pubmed: 22673139
Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):19077-82
pubmed: 24191022
Clin Infect Dis. 2006 Dec 1;43(11):1387-94
pubmed: 17083009
Carbohydr Res. 2003 Nov 14;338(23):2539-47
pubmed: 14670715
Nat Med. 2011 Nov 20;17(12):1602-9
pubmed: 22101769
Lancet. 2004 Jul 24-30;364(9431):365-7
pubmed: 15276396
Annu Rev Immunol. 2010;28:107-30
pubmed: 19968562
J Exp Med. 1980 Aug 1;152(2):361-76
pubmed: 6967514